Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

The treatment landscape for IgA nephropathy is undergoing a profound transformation, driven by updated clinical guidelines, earlier diagnosis, and a rapidly expanding therapeutic arsenal. Where management was once largely reactive, the field is now moving toward earlier, more aggressive, and more targeted intervention aimed at altering disease trajectory.

 at World Congress of Nephrology in Yokohama, Japan, Sayna Norouzi, MD, a clinical nephrologist and associate professor of medicine at Loma Linda University Medical Center, said one of the most significant shifts between the 2021 and 2025 guidelines is the redefinition of high-risk disease.

Previously, proteinuria thresholds of around 1 gram per day were used to guide treatment escalation. Now, patients with proteinuria ≥0.5 g/day are considered at risk, representing a major change in how clinicians identify and manage disease severity. This lower threshold underscores a growing recognition that IgA nephropathy is not a benign condition and can lead to kidney failure if not addressed early.

“The sooner you diagnose these patients, [the sooner] you're going to be able to treat them, and with effective treatment of IgA nephropathy, you might be able to delay dialysis or transplant or complications in general, for your patients,” she said.

The updated guidelines also emphasize more ambitious treatment goals, with a target proteinuria level ideally < 0.3 g/day. Norouzi explains that this shift reflects mounting evidence linking lower proteinuria to improved long-term outcomes, including delayed progression to dialysis or transplant. As a result, clinicians are now encouraged to pursue tighter disease control from the outset.

Another key evolution lies in treatment strategy. Historically, care began with supportive measures like blood pressure control, lifestyle modification, and initiation of RAAS blockade, with additional therapies introduced only after inadequate response. In contrast, the 2025 guidance promotes a more proactive, simultaneous approach, and while supportive care remains foundational, clinicians are now urged to initiate therapies targeting the underlying pathophysiology earlier in the disease course rather than waiting for treatment failure.

This paradigm shift is enabled by a growing list of therapeutic options. Norouzi highlights the emergence of targeted agents, including targeted-release budesonide, endothelin receptor antagonists like sparsentan and atrasentan, complement inhibitors such as iptacopan, and newer APRIL-targeting therapies. Together, these agents provide clinicians with multiple avenues to reduce proteinuria and preserve kidney function.

Despite this progress, she says important questions remain. Norouzi notes that clinical trials provide only a limited snapshot of efficacy and safety, often over relatively short durations. As these therapies enter real-world practice, she says clinicians will need to better understand long-term tolerability, optimal sequencing, and effectiveness in more heterogeneous patient populations.

“We need more data on these medications, on the safety, on how they are going to work over time. The clinical trials are looking at a limited amount of time. They follow patients for 9 months for the initial outcome data, and then they follow patients for 2 years,” Norouzi said. “Once the medication is FDA approved and it's on the market, that's when we are going to have more information and see in real life if patients are tolerating the medications. We're going to hear more about the side effects, how to monitor these patients over time, and if they are responding well to the medications as well.”

Norouzi reports relevant disclosures with Calliditas, Travere, Apellis and others.

Brooks A. KDIGO Releases Updated IgA Nephropathy, IgA Vasculitis Clinical Practice Guideline. HCPLive. September 18, 2025. Accessed March 28, 2026. 

https://www.hcplive.com/view/kdigo-releases-updated-iga-nephropathy-iga-vasculitis-clinical-practice-guideline

Campbell P. Iptacopan Receives Accelerated Approval for Reducing Proteinuria in IgA Nephropathy. August 7, 2024. Accessed April 1, 2026. 

https://www.hcplive.com/view/iptacopan-receives-accelerated-approval-for-reducing-proteinuria-in-iga-nephropathy

Campbell P. Atrasentan (Vanrafia) Receives Accelerated Approval in IgA Nephropathy. April 2, 2025. Accessed April 1, 2026. 

https://www.hcplive.com/view/atrasentan-vanrafia-receives-accelerated-approval-in-igan

Videos

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

 has approved orforglipron (Foundayo), a once-daily oral GLP-1 RA, for chronic weight management in adults with 

 or overweight adults with ≥1 weight-related comorbidity.

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA’s decision and the myriad new treatment opportunities afforded by orforglipron’s clearance for entry into the market.

The approval of orforglipron is supported by the phase 3 ATTAIN clinical development program, which includes 2 global, randomized, double-blind, placebo-controlled trials evaluating efficacy and safety over 72 weeks.¹ The ATTAIN-1 trial enrolled 3,127 adults with obesity or overweight without diabetes, while ATTAIN-2 enrolled more than 1,600 adults with obesity or overweight and type 2 diabetes.

In ATTAIN-1, participants receiving the highest dose of orforglipron achieved a mean weight reduction of approximately 12.4% from baseline at 72 weeks among those who remained on treatment, compared with 0.9% in the placebo group. Reported average absolute weight loss was 27.3 lb versus 2.2 lb, respectively. Across all randomized participants regardless of completion status, mean weight loss was 11.1% with orforglipron compared with 2.1% with placebo.

Secondary outcomes included improvements in cardiometabolic risk markers such as waist circumference, non–high-density lipoprotein cholesterol, triglycerides, and systolic blood pressure. However, detailed peer-reviewed data from ATTAIN-1 and ATTAIN-2 remain limited at the time of reporting, and full efficacy and safety results have not yet been widely published in the medical literature.

The safety profile of orforglipron appears consistent with the GLP-1 receptor agonist class. Common adverse events include gastrointestinal symptoms such as nausea, diarrhea, constipation, vomiting, and abdominal pain. A boxed warning highlights a potential risk of thyroid C-cell tumors, based on findings observed with other GLP-1 receptor agonists in rodent studies, though human relevance remains uncertain.

The magnitude of weight loss observed with orforglipron in ATTAIN-1 appears clinically meaningful but may be modest relative to leading injectable agents. Cross-trial comparisons should be interpreted cautiously due to differences in study populations and designs. Additionally, treatment persistence rates and discontinuation due to adverse events will be important considerations in real-world use.

Ongoing and planned studies are evaluating orforglipron across additional indications, including type 2 diabetes and other cardiometabolic conditions. Future comparative trials against established GLP-1 and dual incretin therapies may help define its role in treatment algorithms.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026. Accessed April 1, 2026. 

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026. Accessed April 1, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program

Podcasts

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

Real-world evidence continues to refine the clinical profile of mavacamten in 

obstructive hypertrophic cardiomyopathy (HCM)

, with new data from both the MARVEL-HCM cohort and a large US Risk Evaluation and Mitigation Strategy (REMS) registry analysis reinforcing its effectiveness and safety in routine practice.

, Matthew Martinez, MD, associate professor of medicine, director of sports cardiology, and director of the Hypertrophic Cardiomyopathy program at Morristown Medical Center/Atlantic Health System, discussed the emerging data from the MARVEL-HCM trial, presented at the 

American College of Cardiology (ACC) Scientific Sessions 2026

“Most often, patients will ask, ‘How long have you been using this drug?’ So, the value of long-term safety data continues to be helpful,” Martinez told 

. “When I’m educating patients about options, I don’t determine what therapy we’re going to use. I give them the option of what’s best for them, and then we can decide together which therapeutic option is the next best step. Ongoing, long-term data continues to be helpful in that discussion.”

In MARVEL-HCM, a multicenter study of 239 patients, women presented at an older age than men (68.5 vs 59.3 years) and with more advanced disease, including higher rates of New York Heart Association (NYHA) class III symptoms and more severe diastolic dysfunction. Over 48 weeks of treatment, patients experienced significant reductions in resting and Valsalva left ventricular outflow tract (LVOT) gradients, improved functional status, and decreased severity of mitral regurgitation. Left ventricular mass index declined in both groups, supporting a role for reverse remodeling, while left ventricular ejection fraction (LVEF) remained stable, and no new safety signals were observed.

These findings are complemented by data from a large REMS-based analysis including more than 6000 patients treated with mavacamten in the United States. In this real-world cohort, 60% of patients were women and nearly two-thirds were older than 60 years, reflecting a population similar to that seen in clinical practice. Over a follow-up period of up to 22 months, reductions in LVOT obstruction were observed, with 70.3% of patients achieving a post-Valsalva gradient <30 mm Hg at 6 months.

Among more than 5,500 patients in the REMS study with monitoring data, 4.6% experienced a reduction in LVEF to <50%, and only 1.3% required hospitalization for heart failure. At the level of individual assessments, these events were infrequent, occurring in <1% of evaluations. Most patients remained on low-dose therapy, with approximately three-quarters maintained on 5 or 10 mg daily.

Taken together, these datasets highlight several clinically relevant themes. First, mavacamten demonstrates consistent effectiveness across diverse patient populations, including those with more advanced disease at baseline. Second, the drug appears to exert favorable effects on cardiac structure and hemodynamics beyond symptom relief. Third, real-world safety outcomes - particularly the low incidence of systolic dysfunction and heart failure - support the feasibility of REMS-guided monitoring in routine care.

The MARVEL-HCM findings also underscore persistent sex-based disparities in disease recognition and severity at treatment initiation. Earlier diagnosis and referral, particularly among women, may further enhance the clinical benefits observed with mavacamten in obstructive HCM.

“I think the real-world data is going to be critical,” Martinez said. “You’re already seeing the ability to be a little more granular with some of the real-world data, such as MARVEL and COLLIGO, because it allows us to ask other questions that may not have been specifically addressed during the clinical trials that led to mavacamten’s approval. All of these real-world studies allow us just a glimpse into what’s happening outside of large academic centers.”

Editors’ Note: Martinez reports disclosures with Bristol Myers Squibb, Cytokinetics, Major League Soccer, and the NHL Combine.

1: Martinez M, Wheeler M, Mehra V, et al. Real-World Evidence from the MARVEL-HCM Multicenter Study of Mavacamten – A Sex-Based Analysis of Baseline Characteristics and Cardiac Structural and Functional Changes. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, LA. March 28-30, 2026.

2: Desai MY, Seto D, Cheung M, et al. Mavacamten: Real-world experience from 22 months of the risk evaluation and mitigation strategy (REMS) program. 

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Tips on Strategies for Psoriasis in Skin of Color, With Eingun James Song, Md

Eingun James Song, MD, the director of clinical research for Frontier Dermatology, spoke in a session at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 titled ‘Inflammatory Skin Diseases in Skin of Color.’

 at AAD in Denver, Song noted while psoriasis is fundamentally the same immunological disease across all skin tones and ethnic groups, outcomes following treatment differ meaningfully and for reasons worth examining carefully. One challenge Song identified was diagnostic uncertainty, noting psoriasis’s presentation appearing differently on darker skin types, with some providers still being undertrained in recognizing and managing inflammatory skin diseases across different varying tones.

“I think that diagnostic uncertainty leads to a delay in care,” Song expressed.

Another issue is inequitable access, including to advanced systemic therapies and even among those who do make it to a specialist. Additionally, Song noted treatment nuances specific to these patients, including a higher risk of post-inflammatory pigmentary alteration and the impact of hair type on which topical formulations are practical to implement.

An important gap mentioned by Song, increasingly highlighted in recent publications, was underrepresentation of skin of color patients in clinical research.

 As a result of this phenomenon, clinicians cannot always confidently generalize findings from large development programs to those whose skin tones were not meaningfully reflected in such trials.

Song was also asked about artificial intelligence (AI) use and its impact on this topic. On the question of AI diagnostic tools and their well-documented limitations in darker skin tones, Song described AI as here to stay. Learning to use AI technology well rather than resist it is key, Song said, though he acknowledged current tools may not yet be fully ready for reliable use across diverse skin tones. Nevertheless, he expressed confidence in iterative improvement.

For any additional information from Song, view his full interview on-site at AAD posted above.

Song has reported serving as an investigator, consultant, and/or speaker for AbbVie, Alphyn Biologics, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, DermBiont, Galderma, Incyte, Janssen, LEO Pharma, MoonLake, Novartis, Ortho, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical Industries, Timber Pharmaceuticals, and UCB.

Song E, et al. F035 Inflammatory Skin Diseases in Skin of Color. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Butera A. Dermatologic Studies Lacking in Diversity Despite Increased Efforts. HCPLive. January 26, 2022. Accessed April 1, 2026. 

https://www.hcplive.com/view/dermatologic-studies-lacking-in-diversity

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Tips on Strategies for Psoriasis in Skin of Color, With Eingun James Song, MD

Joseph Rossano, MD, MS, is the co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.

SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS

Mavacamten exhibited greater reduction of left ventricular outflow compared to placebo in adolescent patients with 

, according to data from the SCOUT-HCM trial.

 in New Orleans, Louisiana, by Joseph Rossano, MD, MS, co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.

“Prior to this, what we used for children was really aimed at helping to alleviate their symptoms, and it wasn’t actually based on very strong evidence that it was helpful for those patients,” Rossano told 

 in an exclusive interview. “It’s really extrapolated from what we use for adult patients. To see such dramatic reductions in the gradients, as well as the improvements in the secondary endpoints, is really encouraging.”

SCOUT-HCM is an ongoing phase 3, double-blind, randomized, placebo-controlled trial consisting of active-treatment and long-term extension periods. Patients were eligible for inclusion if they were aged 12 to <18 years and had received a diagnosis of HCM, which was defined as a maximal left ventricular wall thickness of ≥15 mm (or ≥13 mm with a family history of HCM), had a left ventricular outflow tract pressure gradient during the Valsalva maneuver of ≥30 mmHg, or had a maximal left ventricular outflow tract gradient of ≥50 mmHg, among other criteria. Patients with HCM phenocopies, such as Noonan syndrome and Fabry disease, were excluded.

After confirming eligibility via a 5-week screening period, Rossano and colleagues randomly assigned enrolled patients in a 1:1 ratio to receive mavacamten or placebo during the 28-week treatment period. Mavacamten was started at a once-daily dose of 5 mg in patients with body weight of ≥45 kg (99.2 lb) or 2.5 mg in patients with a body weight of 35 to <45 kg (77.2 to <99.2 lb). This dose could be adjusted down at weeks 5 and 9 or up at weeks 12 and 24 by 1 dose level, based on electrocardiographic assessment of the Valsalva left ventricular outflow tract gradient and LVEF.

The study’s primary endpoint was the change in left ventricular outflow tract pressure gradient provoked by the Valsalva maneuver from baseline. Secondary endpoints included the change from baseline in resting and postexercise left ventricular outflow tract gradients, the maximal left ventricular wall thickness, and the ratio of early mitral inflow velocity to mitral annular early diastolic velocity.

A total of 65 patients were screened for eligibility – of these, 44 were included and assigned to the mavacamten arm (n = 23) or the placebo arm (n = 21). All patients in the mavacamten arm had a dose adherence of ≥80%. Over the course of the study, mean Valsalva left ventricular outflow tract gradient decreased from 78.4 +/- 34.1 mmHg at baseline to 29 +/- 18.3 mmHg at week 28 in the mavacamten group (least-squares mean change, -48.5 mmHg; 95% CI, -63 to -34). The placebo arm exhibited a decrease from 80.8 +/- 47.4 mmHg to 72.7 +/- 40.1 mmHg (least-squares mean change, -0.5 mmHg; 95% CI, -18.7 to 17.6). This corresponded to a significant difference of -48 mmHg (95% CI, -67.7 to -28.3).

Rossano and colleagues reported adverse events in 18 patients (78%) in the mavacamten group versus 17 (81%) in the placebo group. The former saw 2 patients with serious adverse events – 1 patient had 2 episodes of syncope, and the other had an inappropriate shock from an implantable cardioverter-defibrillator. Among the placebo recipients, 2 patients had serious adverse events – 1 had chest pain, and the other had depression with suicidal ideation.

“Importantly, there were really no safety issues,” Rossano said. “We think the medication can be used safely in patients with pretty significant disease. Are there patients who may benefit more than others? Absolutely, that may be the case. I think we just need further study in larger populations over longer periods to try to sort that out.”

Editors’ Note: Rossano reports disclosures with Bristol Myers Squibb, AskBio, Astellas, Merck, and Bayer.

Rossano J, Canter E, Wolf C, et al. Mavacamten in Symptomatic Adolescent Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the Phase 3 Scout-HCM Trial. Abstract presented at the American College of Cardiology Scientific Sessions 2026 in New Orleans, LA. March 28-30, 2026.

Rossano JW, Canter C, Wolf CM, et al. Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy. 

Rossano discusses the results of the phase 3 SCOUT-HCM trial, highlighting mavacamten’s comparative superiority in reducing left ventricular outflow.

Andres Gelrud, MD, is a gastroenterologist at Baptist Health Miami Cancer Institute, part of Baptist Health South Florida

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face. 

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Beyond Chronic Pancreatitis, Rethinking Who Gets EPI and How We Treat It, With Andres Gelrud, MD

Lingfeng Xue, PhD, an old age psychiatry and clinical research assistant at King’s College London.

Analysis of 75,064 UK Biobank participants found late-onset depression associated with worse fluid intelligence and visuospatial memory and a 42–52% increased dementia risk.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Late-Onset Depression Linked to Increased Dementia Risk, With Lingfeng Xue, PhD

Thierry Passeron, MD, PhD, is a professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Next Steps for Upadacitinib in Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Articles

The Agency approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight. It can be taken any time of the day without restrictions on food and water intake.

FDA News

FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions

Christopher Chan, MD, is director of the division of nephrology, professor of medicine, and R Fraser Elliott Chair in Nephrology at Toronto General Hospital, University Health Network.

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.

Chronic Kidney Disease

Entering A New Era of Flexible Dialysis Care, With Christopher Chan, MD

Sofia Holmqvist-Jämsén, PhD, from the University of Helsinki

A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

Respiratory Allergies Linked to Frequent Vocal Symptoms, With Sofia Holmqvist-Jämsén, PhD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

FDA Expands CFTR Modulator Labels, Covering ~95% of US Cystic Fibrosis Patients

Learn smarter oral iron dosing: once daily or every other day to cut GI side effects, boost absorption, and avoid tea/coffee.

Video Series

Oral Iron — Formulation Selection, Dosing Frequency, and Absorption Optimization 

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Type 2 Diabetes

Type 1 Diabetes

Don’t Miss a Beat

The Don't Miss a Beat Podcast is a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

Don't Miss a Beat: MRA Updates at ACC 2026 Scientific Sessions

Professor and Chair of the Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases and in the Peter O'Donnell Jr. School of Public Health at UT Southwestern Medical Center in Dallas

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Latest News

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

Tips on Strategies for Psoriasis in Skin of Color, With Eingun James Song, MD

SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS